See the DrugPatentWatch profile for yervoy

The patent expiry of Yervoy, a cancer treatment drug, is expected to have a significant impact on the pharmaceutical industry. Yervoy, also known as ipilimumab, is a medication used to treat melanoma, a type of skin cancer. It was developed by Bristol Myers Squibb and approved by the US Food and Drug Administration (FDA) in 2011 [1].

The patent expiry of Yervoy, which occurred in 2020 [1], allows other pharmaceutical companies to produce and sell generic versions of the drug. This can lead to increased competition in the market, which can result in a decrease in the price of the drug [2]. This is because generic drugs are typically less expensive to produce and sell than brand-name drugs, as they do not have the same research and development costs [3].

Additionally, the expiration of Yervoy's patent can also lead to increased access to the drug for patients. With the availability of generic versions, more patients may be able to afford the treatment, which can ultimately improve patient outcomes [4].

It's worth noting that, even though the patent has expired, it doesn't mean that generic versions will be available immediately. The FDA still needs to approve these versions, and it can take some time before they become available in the market [5].

In summary, the patent expiry of Yervoy is expected to increase competition in the market, decrease the price of the drug, and increase access to the treatment for patients.

Sources:
[1] <https://www.drugpatentwatch.com/drugs/yervoy>
[2] <https://www.investopedia.com/terms/g/genericdrug.asp>
[3] <https://www.fda.gov/drugs/generic-drugs/generic-drug-facts>
[4] <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4395243/>
[5] <https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/abbreviated-new-drug-application-anda-process>